AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 261 min read$PRE

Rosin Brian J purchased $498K of PRE

Rosin Brian J (CFO of IM8 (US) LLC) purchased 23,100 shares of Prenetics Global Ltd (PRE) at an average of $21.55 ($21.19–$22.80, $0.50M total) across 2 trades over 2026-08-24 to 2026-08-25.

Original reporting
SEC EDGAR · Rosin Brian J
Published Aug 26, 2026, 12:23 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 26, 2026, 12:40 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$PRE
Neutral
high confidence
Mentioned
$PRE
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PRENeutralLow
01

Why it matters

The purchase is modest and unlikely to affect PRE's stock price.

02

Market read

Routine insider purchase with limited trading relevance.

03

What to watch

Potential upcoming product announcements not disclosed.

Relevance 5/10Novelty 4/10Timing: filing date 2026-08-26

Background

Form 4 filing discloses insider trades; used by traders to gauge insider sentiment.

Company-level read

Ticker impact

$PRENeutralHigh confidence
Context

CFO of IM8 purchased 23,100 PRE shares for $497,700 (≈$21.55 avg price) on 2026-08-24/25.

Expected impact

minimal impact; price likely unchanged.

Evidence & confidence

The transaction size is modest relative to market cap and the insider is not a direct executive of Prenetics.

Market effects

Sector

None; biotech sector unchanged.

Regional

No regional effect.

Global

Low; isolated insider transaction.

Counterpoint

What could challenge this read

If the CFO expects near‑term upside, the buy could signal hidden value.

Key entities

  • Company
    Prenetics Global Ltd

    Biotech firm listed on Nasdaq under PRE.

  • Individual
    Rosin Brian J

    CFO of IM8 (US) LLC, reporting a purchase of PRE shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PRE insider trading history →

Related articles

AUG 25
$PREMed

Prenetics (PRE) Q2 2026 Earnings Call Transcript

Prenetics (PRE) reported Q2 2026 revenue of $46.5M, up 29% from Q1 and 3.9x from a year ago, with IM8 contributing $45M. The company raised its full-year revenue guidance to $220M-$230M and initiated 2027 guidance of $400M+. July saw record revenue of $20.9M and a 21% drop in customer acquisition cost. PRE expects Q3 to be its first positive cash flow quarter and plans to launch new products in Q4 and Q1 2027.

yahoo.com2 min
AUG 18
$PREMed

Prenetics Global Q2 Earnings Call Highlights

Prenetics (NASDAQ:PRE) reported preliminary July revenue of $21.4M, including about $20.9M from IM8, and said it reached its highest monthly level. Q2 added 118,000 new IM8 customers (140,000 active subscribers). Q2 gross profit was $30.2M (65% margin); adjusted EBITDA loss was $19M. It expects H2 2026 adjusted EBITDA loss of $8M to $12M and a first positive quarter on an adjusted free-cash-flow basis with a $1B General Catalyst facility.

yahoo.com7 min
AUG 18
$PREHighAI 9/10

Prenetics Global Limited: Prenetics' IM8 Reports Q2 2026 Revenue Growth of 288% YoY; Raises FY 2026 IM8 Revenue Guidance to $220-230 Million; July Was the First Month of Positive Consolidated Adjusted

Prenetics Global (NASDAQ: PRE) reported Q2 2026 revenue of $46.5 million, up about 288% YoY, and IM8 revenue of $45.0 million, up about 359% YoY. Results were within guidance. The company raised FY 2026 total revenue guidance to $220-230 million and initiated FY 2027 IM8 revenue guidance of $400 million+.

finanznachrichten.de6 min
JUL 30
$PREMed

PartnerRe records $447m in first-half net income

PartnerRe reported first-half 2026 net income of $447 million, down from $493 million a year earlier, with operating income of $689 million and annualised operating ROE of 12.6%. Gross premiums written rose to $5.42 billion. Non-life underwriting profit was $396 million with a 85.1% combined ratio. Investment income increased to $491 million, but unrealised losses reduced net investment return.

royalgazette.com4 min